{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-094788","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.608443+00:00","generated_at":"2026-05-31T10:28:55.277329+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences Q2 net loss $8.4M; cash $12.1M, plans Phase 1b","bullets":["Net loss for Q2 2024 of $8.4M ($5.13 per share) vs $1.4M loss in Q2 2023.","Net loss for H1 2024 of $11.1M ($8.13 per share) vs net income of $4.7M in H1 2023.","Cash and equivalents $12.1M as of June 30, 2024, up from $12.0M at Dec 31, 2023.","Completed Phase 1 dosing of Gemini; safety endpoint met with biomarker activity.","Phase 1b study in CKD patients expected to start in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-094788","json":"https://secwatch.observer/filing/0000950170-24-094788.json","markdown":"https://secwatch.observer/filing/0000950170-24-094788.md","text":"https://secwatch.observer/filing/0000950170-24-094788.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024094788/0000950170-24-094788-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024094788/revb-20240809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:28:55.277329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}